An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis

An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis

Patient-reported outcomes are valuable for assessing new psoriasis therapies. This study investigated patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with ixekizumab or ustekinumab, dosed according to their respective labels, for 52 weeks (IXORA-S-NCT02561806)....

Full description

Bibliographic Details
Main Authors:	Lluís Puig, Mark Lomaga, Kristin Hollister, Yves Dutronc, Lovisa Berggren, Peter C.M. van de Kerkhof
Format:	Article
Language:	English
Published:	Society for Publication of Acta Dermato-Venereologica 2020-12-01
Series:	Acta Dermato-Venereologica
Subjects:	patient-reported outcomes health-related quality of life ixekizumab ustekinumab
Online Access:	https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3700

Similar Items

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
by: Norman Wasel, et al.
Published: (2020-05-01)

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study
by: Emanuela Zagni, et al.
Published: (2021-09-01)

Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes
by: Luís Puig, et al.
Published: (2019-08-01)

Erythrodermic psoriasis after discontinuation of ixekizumab
by: Kathryn Anne Potter, MD, et al.
Published: (2018-01-01)

Toxoplasmosis in a patient receiving ixekizumab for psoriasis
by: Yolanka Lobo, BPhysio, MBBS, et al.
Published: (2020-03-01)

Ixekizumab May Improve Renal Function in Psoriasis
by: Giuseppe Fabrizio Amoruso, et al.
Published: (2021-05-01)

Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system
by: E. A. Pyadushkina, et al.
Published: (2021-02-01)

Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial
by: Lyn Guenther, et al.
Published: (2020-01-01)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
by: Hanley TL, et al.
Published: (2017-03-01)

Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies
by: Gil Yosipovitch, et al.
Published: (2018-11-01)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Sekhon S, et al.
Published: (2017-11-01)

Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
by: Giunta A, et al.
Published: (2017-06-01)

Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies
by: Bernard Combe, et al.
Published: (2021-01-01)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
by: Jerry Bagel, et al.
Published: (2018-10-01)

Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis
by: Maeve Lynch, MD, MBBChBAO, et al.
Published: (2017-05-01)

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
by: Blauvelt A, et al.
Published: (2020-03-01)

Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders
by: I. V. Rychkova, et al.
Published: (2019-08-01)

Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
by: Kazemi T, et al.
Published: (2017-04-01)

Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks
by: Helena Marzo-Ortega, et al.
Published: (2020-08-01)

Changes in metabolic parameters in psoriasis patients treated with interleukin-12/23 blockade (ustekinumab)
by: Chau Yee Ng, et al.
Published: (2020-01-01)

Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks
by: Atul Deodhar, et al.
Published: (2021-09-01)

Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab
by: Amy J. Petty, BS, et al.
Published: (2020-08-01)

Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab
by: Jeanette Halskou Hesselvig, et al.
Published: (2017-12-01)

Tineа Corporis with Trichophyton Rubrum Mimicking a Flare-Up of Psoriasis UnderTreatment with IL17-Inhibitor Ixekizumab
by: Vladimir Emelianov, et al.
Published: (2021-07-01)

Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis
by: A. M. Dadalova, et al.
Published: (2020-11-01)

Successful Treatment of Pityriasis Rubra Pilaris with Ixekizumab
by: Kathrin Hanfstingl, et al.
Published: (2018-05-01)

Immunopathogenetic mechanisms of action of ustekinumab, a new drug for the treatment of psoriatic arthritis and psoriasis
by: T. V. Korotaeva, et al.
Published: (2015-06-01)

Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience
by: Ting-Shun Wang, et al.
Published: (2017-03-01)

Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature
by: Pablo Santa María, et al.
Published: (2017-10-01)

Pyoderma gangrenosum in a patient on ixekizumab
by: Ilana R. Pollack, MSc, et al.
Published: (2021-10-01)

Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension
by: Alexandra B. Kimball, et al.
Published: (2017-10-01)

Effectiveness of resuming ustekinumab therapy in psoriasis patients with metabolic disorders. Clinical experience
by: I. V. Rychkova, et al.
Published: (2019-02-01)

Erythema multiforme after initiation of anti interleukin-12/23 (ustekinumab) treatment for plaque psoriasis
by: Martina Burlando, MD, et al.
Published: (2020-05-01)

Ustekinumab treats psoriasis by suppressing RORC and T-box but its suppression of GATA restrains its efficacy
by: Lun-Fei Liu, et al.
Published: (2019-04-01)

Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients
by: Beltammer Belkais, et al.
Published: (2019-03-01)

Ixekizumab Survival in Heavily Pretreated Patients with Psoriasis: A Two-year Single-centre Retrospective Study
by: Shany Sherman, et al.
Published: (2020-12-01)

Severe de novo Ulcerative Colitis following Ixekizumab Therapy
by: Jobin Philipose, et al.
Published: (2018-10-01)

Severe drug-associated colitis with Crohn’s features in setting of ixekizumab therapy for chronic plaque psoriasis
by: Xin Mu, et al.
Published: (2021-10-01)

Ustekinumab-induced remission of recalcitrant guttate psoriasis: A case series
by: Grace C. Brummer, BS, et al.
Published: (2017-09-01)

The use of ustekinumab in patients with psoriasis and coexisting renal or hepatic dysfunction – a report of two cases
by: Hubert Arasiewicz, et al.
Published: (2014-10-01)